In the phase I/II CHORUS trial, adding the IL-1 beta inhibitor canakinumab to concurrent chemoradiotherapy and consolidative durvalumab achieved a 24-month progression-free survival rate of 67% in unresectable stage III non-small cell lung cancer. The report positions the regimen as an escalated anti-inflammatory strategy layered onto established chemoradiation and PD-(L)1 pathway blockade. The trial result is framed as favorable within the study’s early-stage evaluation, where safety and longer-term disease control are closely scrutinized. By combining an inflammatory cytokine axis with standard immuno-radiation care, the approach targets a rationale not covered by checkpoint inhibitors alone. For thoracic oncology, the headline matters as it suggests a possible avenue to improve durability in a disease setting where relapse remains common, though further phase testing is implied by the trial phase and design.